Results 41 to 50 of about 338,912 (243)

Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts

Leukemia, 2018
A total of 410 patients with blast phase myeloproliferative neoplasm (MPN-BP) were retrospectively reviewed: 248 from the Mayo Clinic and 162 from Italy. Median survival was 3.6 months, with no improvement over the last 15 years.
A. Tefferi, M. Mudireddy, F. Mannelli, K. Begna, M. Patnaik, C. Hanson, R. Ketterling, N. Gangat, Meera Yogarajah, V. De Stefano, F. Passamonti, V. Rosti, M. Finazzi, A. Rambaldi, A. Bosi, P. Guglielmelli, A. Pardanani, A. Vannucchi   +17 more
semanticscholar   +1 more source

Online yoga in myeloproliferative neoplasm patients: results of a randomized pilot trial to inform future research

BMC Complementary and Alternative Medicine, 2019
BackgroundMyeloproliferative neoplasm (MPN) patients suffer from significant symptoms, inflammation and reduced quality of life. Yoga improves these outcomes in other cancers, but this hasn’t been demonstrated in MPNs.
J. Huberty, Ryan Eckert, A. Dueck, H. Kosiorek, L. Larkey, K. Gowin, R. Mesa   +6 more
semanticscholar   +1 more source

Smartphone-Based Meditation for Myeloproliferative Neoplasm Patients: Feasibility Study to Inform Future Trials

JMIR Formative Research, 2018
Background Myeloproliferative neoplasm (MPN) patients often report high symptom burden that persists despite the best available pharmacologic therapy.
J. Huberty, Ryan Eckert, L. Larkey, J. Kurka, Sue A Rodríguez De Jesús, Wonsuk Yoo, R. Mesa   +6 more
semanticscholar   +1 more source

Molecular mechanisms associated with leukemic transformation of MPL-mutant myeloproliferative neoplasms

Haematologica, 2010
Somatic activating mutations in MPL, the thrombopoietin receptor, occur in the myeloproliferative neoplasms, although virtually nothing is known about their role in evolution to acute myeloid leukemia. In this study, the MPL T487A mutation, identified in
Philip A. Beer, Christina A. Ortmann, Frank Stegelmann, Paola Guglielmelli, John T. Reilly, Thomas S. Larsen, Hans C. Hasselbalch, Alessandro M. Vannucchi, Peter Möller, Konstanze Döhner, Anthony R. Green   +10 more
doaj   +1 more source

Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome

Haematologica, 2017
Chronic eosinophilic leukemia, not otherwise specified can be difficult to distinguish from idiopathic hypereosinophilic syndrome according to the current World Health Organization guideline.
Sa A. Wang, Robert P. Hasserjian, Wayne Tam, Albert G. Tsai, Julia T. Geyer, Tracy I. George, Kathryn Foucar, Heesun J. Rogers, Eric D. Hsi, Bryan A. Rea, Adam Bagg, Carlos E. Bueso-Ramos, Daniel A. Arber, Srdan Verstovsek, Attilio Orazi   +14 more
doaj   +1 more source

Hybrid or Mixed Myelodysplastic/Myeloproliferative Disorders – Epidemiological Features and Overview

Frontiers in Oncology, 2021
The WHO-category Myelodysplastic/Myeloproliferative neoplasms (MDS/MPNs) recognizes a unique group of clonal myeloid malignancies exhibiting overlapping features of myelodysplastic as well as myeloproliferative neoplasms.
Andrea Kuendgen, Annika Kasprzak, Ulrich Germing   +2 more
doaj   +1 more source

Unfolding the Role of Calreticulin in Myeloproliferative Neoplasm Pathogenesis

Clinical Cancer Research, 2019
In 2013, two seminal studies identified gain-of-function mutations in the Calreticulin (CALR) gene in a subset of JAK2/MPL-negative myeloproliferative neoplasm (MPN) patients.
Tiffany R. Merlinsky, R. Levine, E. Pronier   +2 more
semanticscholar   +1 more source

American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel

Arthritis &Rheumatology, EarlyView.
Objective Vacuoles E1 enzyme X‐linked autoinflammatory somatic syndrome (VEXAS) is a recently identified rare genetic disorder associated with somatic mutations in the UBA1 gene. VEXAS presents with a combination of inflammatory and hematologic manifestations, leading to increased morbidity and mortality.
Arsene Mekinian, Sophie Georgin‐Lavialle, Marcela A. Ferrada, Sinisa Savic, Matthew J. Koster, Olivier Kosmider, Thibault Comont, Mael Heilblig, Juan I. Arostegui, Annmarie Bosco, Rim Bourguiba, Katherine R. Calvo, Catherine Cargo, Chiara Cattaneo, François Chasset, Henrique Coelho, Corrado Campochiaro, Francesca Crisafulli, Stephanie Ducharme‐Benard, Raquel Faria, Franco Franceschini, Micol Frassi, Emma M. Groarke, Carmelo Gurnari, Yervand Hakobyan, Yvan Jamilloux, Ciprian Jurcut, Yohei Kirino, Austin Kulasekararaj, Hiroyoshi Kunimoto, Lauren M. Madigan, Heřman F. Mann, Chiara Marvisi, Marcin Milchert, Sara Morais, Katja Sockel, Francesco Muratore, Hideaki Nakajima, Mrinal M. Patnaik, Luísa Regadas, Marie Robin, Abraham Rutgers, Carlo Salvarani, Anthony M. Sammel, Joerg Seebach, Pierre Sujobert, Alessandro Tomelleri, Geoffrey Urbanski, Frédéric Vandergheynst, Romana Vieira, David S. Viswanatha, Ewa Więsik‐Szewczyk, Elisa Diral, Benjamin Terrier, Bhavisha A. Patel, Pierre Fenaux, Peter C. Grayson, David B. Beck, on behalf of the International VEXAS working group, and with endorsement of EuroBloodNet, the European Reference Network in Rare Hematological Diseases, Heřman Mann, Benjamin Terrier, François Chasset, Sophie Georgin Lavialle, Alessandro Tomelleri, Campochiaro Corrado, Carlo Salvarani, Francesca Crisafulli, Franco Franceschini, Micol Frassi, Yohei Kirino, Ewa Więsik‐Szewczyk, Marcin Milchert, Raquel Faria, Ciprian Jurcut, Joerg Seebach, Sinisa Savic, David Beck, Lauren Madigan, Matthew Koster, Patnaik Mrinal, Olivier Kosmider, Pierre Sujobert, Juan I. Arostegui, Catherine Cargo, David Viswanatha, Yervand Hagopian, Mael Heilblig, Pierre Fenaux, Thibault Comont, Bruno Alessandro, Chiara Cattaneo, Elisa Diral, Sara Morais, Austin Kulasekarara, Emma Groarke, Katherine Calvo, Patel Bhavisha, Anthony Sammel, Arsene Mekinian, Benjamin Terrier, Marie Robin, Sophie Georgin Lavialle, Katja Sockel, Yvan Jamilloux, Carmelo Gurnari, Henrique Coelho, Romana Vieira, Rim Bourguiba, Marcela Ferrada, Peter Grayson   +111 more
wiley   +1 more source

Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: a dual-center, propensity score-matched analysis

Leukemia and Lymphoma, 2019
Ruxolitinib is a JAK1/2 inhibitor approved for the treatment of myelofibrosis (MF) and polycythemia vera (PV). Recent data have suggested the possibility of increased infectious and secondary malignancy rates in patients treated with ruxolitinib.
D. Tremblay, Amber C King, Lihua Li, E. Moshier, Alexander Coltoff, A. Koshy, M. Kremyanskaya, R. Hoffman, M. Mauro, R. Rampal, J. Mascarenhas   +10 more
semanticscholar   +1 more source

Activating JAK2 mutants reveal cytokine receptor coupling differences that impact outcomes in myeloproliferative neoplasm

Leukemia, 2017
Janus tyrosine kinase 2 (JAK2) mediates downstream signaling of cytokine receptors in all hematological lineages, yet constitutively active JAK2 mutants are able to drive selective expansion of particular lineage(s) in myeloproliferative neoplasm (MPN ...
H. Yao, Yue Ma, Z. Hong, Lequn Zhao, Sara A. Monaghan, Ming-Chang Hu, Lily Jun-shen Huang   +6 more
semanticscholar   +1 more source